NRG/GOG Foundation

Uterine Corpus Subcommittee

Gynecologic Oncology Group

Gynecologic Oncology Group

NRG ONCOLOGY

Advancing Research. Improving Lives.™

GOG Foundation/Partners

Gynecologic Oncology Group

Pelvic Recurrence

- 2/25/2008
- Endorsed by RTOG
- 108/154 accrued



Institution IMRT Credentialing is required when IMRT is to be used before registering any patient on this trial. A Knowledge Assessment for this study must be completed by the treating radiation oncologist before registering patients on this trial.

For patients with tumors involving the distal vagina and clinically negative groins, the bilateral inguino-femoral lymph node regions should be treated to 4500 cGy.

3-D conformal or IMRT boost is allowed for patients who are not candidates for brachytherapy.

Leiomyosarcoma: Stage I



4 Jun 2012 opened
38/216 accrued
9 Sep 2016 closed

GOG TRIALS IN DEVELOPMENT

- **NYG- GY011 (UC 1306):** A randomized phase II study evaluating the role of maintenance therapy with cabozantinib in High Grade Uterine Sarcoma (HGUS) after stabilization or response to chemotherapy following surgery or in metastatic first line treatment

Approved by CTEP

EORTC 62113-55115 / NRG-GY011
High Grade Undifferentiated Uterine Sarcoma



International Rare Cancers Initiative

LOW-RISK GESTATIONAL TROPHOBLASTIC NEOPLASIA



18 Jun 2012 opened
GCIG collaboration
57/384 accrued
20 Sep 2016 closed

GOG Gynecologic Oncology Group